Shares of Replimune Group Inc. (REPL) are soaring 6.26% in pre-market trading on Thursday following the release of the company's fiscal fourth quarter and year-end 2025 financial results. The biotechnology firm, which focuses on developing oncolytic immuno-gene therapies for cancer treatment, saw its stock climb despite reporting a significant net loss.

According to the financial report, Replimune Group posted a net loss of USD 74.1 million for the fourth quarter. However, investors appear to be looking beyond this figure, suggesting that other aspects of the company's performance or future outlook may be more promising. The full details of the financial results and corporate update were not immediately available, but the market's positive reaction indicates that there may be encouraging developments in Replimune's pipeline or operational progress.

The stock's surge in the face of a substantial net loss could be attributed to several factors. Investors might be focusing on potential revenue growth, advancements in the company's drug candidates, or positive guidance for future periods. Additionally, in the biotechnology sector, progress in clinical trials or regulatory milestones often outweigh current financial performance in terms of stock valuation. As the trading day unfolds, more information may emerge to explain the market's enthusiastic response to Replimune's latest financial report.